

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 7/04, A61K 39/205, A61P 31/14	A1	(11) International Publication Number: WO 00/32755 (43) International Publication Date: 8 June 2000 (08.06.00)
(21) International Application Number: PCT/EP99/09101 (22) International Filing Date: 19 November 1999 (19.11.99) (30) Priority Data: 98204001.6 27 November 1998 (27.11.98) EP (71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL). (72) Inventors; and (75) Inventors/Applicants (for US only): MEBATSION, Teshome [NL/NL]; De Ribes 20, NL-5831 RJ Boxmeer (NL). CONZELMANN, Karl, Klaus [DE/DE]; Ammerseestrasse 34, D-82061 Neuried (DE). (74) Agent: C.M. OGILVIE EMANUELSON; P.O. Box 20, NL-5340 BH Oss (NL).		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: STABLE, ATTENUATED RABIES VIRUS MUTANTS AND LIVE VACCINES THEREOF (57) Abstract The present invention relates to recombinant rabies virus mutants comprising a mutation in the viral genome, whereby said mutation comprises at least a substitution of the Arg ₃₃₃ codon in the gene encoding the G protein with a codon that differs by three nucleotides from said Arg ₃₃₃ codon. These rabies virus mutants have a glycoprotein G that comprises an amino acid at position 333 which is encoded by a codon that differs by all three nucleotides from the Arg codon in amino acid position 333 in the glycoprotein of the parental virus. Said recombinant rabies virus mutants are stable and non-pathogenic in immune competent animals and are suitable for use in a live, attenuated anti-rabies vaccine.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
HJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

STABLE, ATTENUATED RABIES VIRUS MUTANTS AND LIVE VACCINES THEREOF

The present invention relates to attenuated rabies virus mutants and live attenuated anti-rabies vaccines comprising said mutants

5 Rabies is a disease that can occur in all warm-blooded species and is caused by rabies virus (RV). Infection with RV followed by the outbreak of the clinical features in nearly all instances results in death of the infected species. In Europe, the USA and Canada wild life rabies still exists and is an important factor in the cause of most human rabies cases that occur. On the other hand, urban rabies constitutes the major cause of human rabies in developing countries.

10 Rabies virus (RV) is a non-segmented negative-stranded RNA virus of the Rhabdoviridae family. RV virions are composed of two major structural components: a nucleocapsid or ribonucleoprotein (RNP), and an envelope in the form of a bilayer membrane surrounding the RNP core. The infectious component of all Rhabdoviruses is the RNP core which consists of the RNA genome encapsidated by the nucleocapsid (N) protein in
15 combination with two minor proteins, i.e. RNA-dependent RNA-polymerase (L) and phosphoprotein (P). The membrane surrounding the RNP core consists of two proteins: a trans-membrane glycoprotein (G) and a matrix (M) protein located at the inner site of the membrane.

20 The G protein, also referred to as spike protein, is responsible for cell attachment and membrane fusion in RV and additionally is the main target for the host immune system. The amino acid region at position 330 to 340 (referred to as antigenic site III) of the G protein has been identified to be responsible for the virulence of the virus, in particular the Arg residue at position 333. All RV strains have this virulence determining antigenic site III in common.

25 An effective way to control rabies is vaccination with inactivated RV or with attenuated vaccine strains of RV. In general, attenuated live anti-rabies vaccines are preferred because they often evoke a long lasting immune response usually based on both humoral and cellular reactions. Currently available attenuated live anti-rabies vaccines are based on attenuated RV

vaccine strains including the SAD Bern strain or the SAD B19 strain, however these vaccines still have undesired residual pathogenicity.

Several attempts have been made to obtain non-pathogenic RV strains for use in a live vaccine. European Patent 350398 describes an avirulent RV mutant SAG1 derived from the Bern SAD strain of RV in which the glycoprotein possesses Ser instead of Arg at position 333. The avirulent mutant SAG1 was obtained under selection pressure of specific monoclonal antibodies on the SAD Bern strain. In adult mice SAG1 has been found to be non-pathogenic. However, pathogenic revertants of the attenuated virus occurred at a frequency of 1 in 10,000 (Lafay et al, Vaccine 12. pp. 317-320, 1994). The genetic instability of this mutant renders it unsuitable for safe vaccination.

European patent application 583998 describes another attenuated RV mutant, SAG2, in which Arg at position 333 has been substituted by Glu in the glycoprotein. SAG2 is non-pathogenic for adult mice when administered by various routes. SAG2 is currently used for oral vaccination of foxes particularly in France. Because this mutant also has the potential to revert to the pathogenic parental strain, the vaccine is produced in the presence of specific monoclonal antibodies to prevent reversion (Blancou and Meslin, 1996; In Laboratory techniques in rabies, pp. 324-337). Since these specific monoclonal antibodies are not present in inoculated animals, vaccination with such mutant still has the risk that the mutant reverts to virulence in the inoculated animal resulting in disease outbreaks in the inoculated animals and possible spread of the pathogen to other animals.

Hence there is an ongoing need for attenuated live anti-rabies vaccines which do not have residual pathogenicity or the potential to revert to the pathogenic variant. The present invention provides for such vaccines.

According to the present invention it was found that stable, attenuated RV mutants could be obtained by a mutation in the G-protein gene of the viral genome, said mutation comprising substitution of the Arg₃₃₃ codon with a codon that differs by all three nucleotides from the Arg₃₃₃ codon. For the purpose of this invention, the term "Arg₃₃₃ codon" is defined as the codon in the G-protein gene of the viral genome that encodes Arg₃₃₃ in the G protein. The

term "Arg₃₃₃" is defined as the Arg residue at position 333 of the RV G protein. In RV strain SAD and strains derived therefrom the Arg₃₃₃ codon is AGA and mutation of this codon into a codon that differs by all three nucleotide from said Arg₃₃₃ codon resulted in stable and attenuated RV mutants. Preferably the Arg₃₃₃ codon was mutated into GAC, CAG, TCC, GAG, CAC or CAT. Similar mutations can be carried out with other RV strains to obtain stable attenuated mutants. Mutations according to the invention were found to be stable and the resulting RV mutants were attenuated and did not revert to pathogenicity. These stable, attenuated RV mutants are very suitable for use in a vaccine. A great advantage of the invention is furthermore that vaccines comprising the RV mutants according to the invention can be produced without the need of specific monoclonal antibodies. Hence vaccine production becomes more simple and easier to carry out..

Thus in a first aspect the present invention provides for recombinant RV mutants comprising a mutation in the viral genome, whereby said mutation comprises at least a substitution of the Arg₃₃₃ codon with a codon that differs by three nucleotides from said Arg₃₃₃ codon. Preferably the mutants are mutants of an RV strain in which the Arg₃₃₃ codon is an AGA triplet. More preferably the mutants according to the invention are mutants of RV strain SAD and its derivatives, especially RV strain SAD B19.

Preferred RV mutants according to the invention are RV mutants in which the Arg₃₃₃ codon AGA has been substituted with a GAC triplet, CAG triplet, TCC triplet, GAG triplet, CAC triplet or CAT triplet. Much preferred RV mutants are RV mutants in which the Arg₃₃₃ codon AGA has been substituted with a GAC triplet or CAC triplet. Particularly preferred are recombinant RV mutant strains SAD D29 and SAD H31, in which the Arg₃₃₃ codon in the genome of RV strain SAD B19 has been substituted with a GAC triplet and CAC triplet, respectively.

Thus the present invention provides for stable, attenuated recombinant RV mutants in which the G protein of said mutant comprises an amino acid at position 333 which is encoded for by a codon which differs by all three nucleotides from the Arg₃₃₃ codon of the parental virus. It was found that the recombinant RV mutants according to the invention are non-pathogenic in immune competent animals and were found to be highly stable. Surprisingly,

even after 25 passage experiments in cell culture no alterations were observed. All cell culture passages were carried out in the absence of monoclonal antibodies. Moreover the mutants remained non-pathogenic for adult mice even after a passage in suckling mice. The substitutions at position 333 of the G protein in no way affected the growth rate of the virus in BSR cells and the final titre was similar to the parental strain. This makes the recombinant RV mutants according to the invention very suitable for use in a live anti-rabies vaccine.

In addition to substitution of the Arg codon at amino acid position 333 in the G protein, the recombinant RV mutants according to the present invention may comprise other substitutions that affect the amino acids of Antigenic site III of the glycoprotein. Preferably these substitutions are made in the codons that encode the amino acids of Antigenic site III of the glycoprotein, more preferably in the codons that correspond to amino acid position 330 and/or 336 in the G protein. The recombinant RV mutants according to the present invention may furthermore comprise other mutations or modifications including heterologous genes e.g. a gene encoding a G protein of a different RV strain.

The recombinant RV mutants according to the invention can be obtained using recombinant DNA technology and site-specific mutagenesis to introduce the desired mutation in contrast to prior art alteration by chance using monoclonal antibodies. Direct genetic manipulation of RV can be carried out using the reverse genetics system described in Schnell et al, 1994; EMBO J. Vol. 13, No. 18, pp. 4195-4203 and European patent application 0 702 085, both of which are hereby incorporated by reference. Site-specific mutagenesis can be carried out according to the method described by Kunkel, T.A., Roberts, J.D. and Zakour, R.A. (1987): *Rapid and efficient site-specific mutagenesis without phenotypic selection*. Methods Enzymology Vol. 154, pp. 376-382. A full length cDNA clone of the vaccine strain SAD B19 described in Schnell et al, supra, was used as basis to introduce codons that differed from the Arg triplet of the parental RV strain in all three nucleotides for the generation of recombinant RV mutants according to the invention. RV mutants according to the invention can be obtained by a) introducing the desired mutation into the RV full-length cDNA clone, b) simultaneous expression of a full length antigenomic RV RNA from the modified cDNA and RV N, P, and L

proteins from plasmids transfected into T7- RNA polymerase expressing cells, and 3) isolating the RV mutant viruses produced by said cells.

The recombinant RV mutants according to the invention can be grown on a cell culture derived from for example BHK cells or human diploid cells. The viruses thus grown can be
5 harvested by collecting the tissue cell culture fluids and/or cells.

In a further aspect the present invention provides for attenuated live anti-rabies vaccines comprising one or more recombinant RV mutants according to the invention. Preferably an attenuated live anti-rabies vaccine according to the invention comprises a recombinant RV mutant derived from the RV strain SAD B19. Attenuated live anti-rabies
10 vaccine according to the invention that are especially preferred comprises recombinant RV mutant strains in which the Arg₃₃₃ codon in the viral genome has been substituted with a GAC triplet and CAC triplet, respectively. More specifically, the vaccine according to the invention comprises a recombinant RV mutant strain in which Arg₃₃₃ codon in the viral genome has been substituted with the triplet GAC, resulting in replacement of Arg with Asp at position 333 of the
15 G protein. Particular preferred are vaccines comprising recombinant RV mutant strain SAD D29. The vaccine according to the invention have the great advantage that they can be produced in the absence of specific monoclonal antibodies.

The vaccine according to the invention can be prepared using standard techniques available in the art. In general the vaccine is prepared by mixing the attenuated recombinant
20 RV mutant according to the invention with a pharmaceutical acceptable carrier or diluent.

Pharmaceutical acceptable carriers or diluents that can be used to formulate a vaccine according to the invention are sterile and physiological compatible such as for example sterile water, saline, aqueous buffers such as alkali metal phosphates (e.g. PBS), alcohols, polyols, and the like. In addition the vaccine according to the invention may comprise other additives
25 such as adjuvants, stabilisers, anti-oxidants, preservatives and the like.

Suitable adjuvants include but are not limited to aluminium salts or gels, carbomers, non-ionic blockcopolymers, tocopherols, monophospheryl lipid A, muramyl dipeptide, oil

emulsions (w/o or o/w), cytokines, and saponins such as Quil A. The amount of adjuvant added depends on the nature of the adjuvant itself.

Suitable stabilisers for use in a vaccine according to the invention are for example carbohydrates including sorbitol, mannitol, starch, sucrose, dextrin, and glucose, proteins such
5 as albumin or casein, and buffers like alkaline phosphates.

Suitable preservatives include, amongst others, thimerosal, merthiolate, and gentamycin.

The attenuated live anti-rabies vaccine according to the invention can be administered to warm-blooded mammals, including humans, dogs, foxes, racoons and skunks via injection
10 (intramuscularly, intradermally, or subcutaneously), spray or aerosol (intranasally), or per oral. Preferably the vaccine is administered to the subjects per oral, especially in case of wild-life animals or stray-dogs. For oral administration the vaccine is mixed with a suitable carrier such as, for example, proteins or oils of vegetable or animal origin. For oral delivery, the vaccine formulation may further be encapsulated with baits prepared from metabolisable substances
15 of animal or vegetable origin.

The useful dosage to be administered will vary, depending on the type of warm-blooded mammals to be vaccinated, the age, weight and mode of administration. In general a suitable dosage will vary between 10^2 to 10^8 TCID₅₀/mammal.

The following examples will illustrate the invention without limiting the invention thereto.

20 METHOD AND MATERIAL

Construction of cDNA clones

Site directed mutagenesis by the method of Kunkel et al, 1987; *Rapid and efficient site-specific mutagenesis without phenotypic selection*, Methods Enzymology, Vol 154, pp. 376-382 was performed with 21-mer oligonucleotides to exchange three nucleotides of pT7T-G
25 (Conzelmann and Schnell, 1994; J. Virology, Vol. 68, No. 2, pp. 713-719). The resulting plasmids encoded modified RV glycoprotein (G protein) in which Arg at position 333 (SAD B19 position 4370-4372) of the mature RV G protein was replaced with different amino acids (see

Table I). In order to incorporate the introduced mutations into a full length RV cDNA clone (pSAD L16), an *Stu*//*Ppu**MI* cDNA fragment comprising SAD B19 nucleotides 4015-4470 was exchanged.

5 Table I: RV cDNA clones and the codons that encode for the amino acid residues at antigenic site III of the glycoprotein of the resulting recombinant RV mutant viruses.

Plasmid	Position of codon in G gene	Amino acid change	Codon change
pSAD L16	330 333 336	K R N	AAG AGA AAT
pSAD Q1	--- 333 ---	- Q -	--- CAG ---
pSAD S11	--- 333 ---	- S -	--- TCC ---
pSAD E18	--- 333 ---	- E -	--- GAG ---
pSAD D29	--- 333 ---	- D -	--- GAC ---
pSAD TQ6	330 333 ---	T Q -	-C- CAG ---
pSAD H31	--- 333 ---	- H -	--- CAC ---
pSAD G4 *)	--- 333 ---	- G -	--- G-T ---
pSAD I21 *)	--- 333 ---	- I -	--- -TC ---
pSAD NM7 *)	330 333 ---	N M -	--C -TG ---
pSADTMD23*	330 333 336	T M D	-C- -TG G-C

*) comparative examples: RV cDNA clones in which the codon differs by only two nucleotides from the Arg codon

Recovery and propagation of antigenic site III mutants

10 Transfection experiments were carried out as described previously (Conzelmann and Schnell, 1994; J. Virology, Vol. 68, No. 2, pp. 713-719). Approximately 10^6 BSR cells were infected with the recombinant vaccinia virus vTF7-3 (Fuerst et al., 1986) and then transfected with a plasmid mixture containing 5 μ g of pT7T-N, 2.5 μ g of pT7T-P, 2.5 μ g of pT7T-L and with 4 μ g of a plasmid encoding the full length antigenomic RNA by using the Stratgene mammalian transfection kit (CaPO₄ protocol). Isolation of the transfectant virus and removal of vaccinia
 15 virus was carried out as described in Schnell et al., 1994 supra. Infection of cells was

monitored by direct immunofluorescence with an anti-RV nucleoprotein conjugate (Centocor) and the recombinant RV's were further passaged until infection of the entire monolayer was achieved. The resulting virus stocks were titrated by end point dilution. Twenty five serial passages in BSR cell cultures were carried out at a multiplicity of infection (moi) of 0.01.

5 ***RT-PCR and Sequence analysis***

To determine the stability of the recombinant viruses, 25 successive passages in BSR cells were performed. RT-PCR was performed on 1 µg of total RNA isolated from infected cells using the "Titan One Tube RT-PCR System" according to suppliers instructions (Boehringer Mannheim). The PCR products were analysed on 1% agarose gels and used directly for
10 sequencing.

Mice inoculation and virus neutralisation

Groups of 3 week-old NMRI mice were inoculated intracerebrally (ic) with 0.03 ml of a virus suspension (3,000 to 9,000,000 ffu/mouse) and observed for rabies symptoms. To determine whether pathogenic revertants appear after passaging in suckling mice, recombinant viruses
15 were inoculated ic into two day-old mice. A 20% brain suspension was prepared from dead mice and inoculated into 3 week-old mice. Serum samples were collected from surviving mice 21 days after infection. To determine the neutralising activity of the mouse sera, serial 5 fold dilution's of the sera were incubated with 40 ffu of CVS strain. After 1 hour BHK cells were added into the virus-serum mixture, incubated for 24 hours and examined by direct
20 fluorescence. For data see table II..

Table II: Antigenic site III mutants; mutants correspond to the cDNA clones of Table I (rec = recombinant; RV = rabies virus; pfu = plaque forming units; ic = intracerebral; ftu = focus forming units; W = weanling mice 3 week-old; S = suckling mice 2 day-old; Ab = antibody; ND = not done)

rec RV mutant	Titre in BSR pfu/ml	pathogenicity in mice (% mortality after ic.)		Dose ftu/mouse	pathogenicity after passage in suckling mice	Ab-titre after ic. in IU
		W	S			
SAD L16	1 X 10 ⁸	100	100	3,000	ND	ND
SAD Q1	..	0	100	3,000,000	0	62.5
SAD S11	..	0	100	3,000,000	ND	ND
SAD E18	..	0	100	3,000,000	ND	312.5
SAD D29	2 x 10 ⁸	0	100	6,000,000	0	312.5
SAD TQ6	7 x 10 ⁷	0	100	2,000,000	0	ND
SAD H31	3 x 10 ⁸	0	100	9,000,000	0	ND
SAD G4	1 x 10 ⁸	0	100	3,000,000	ND	37.5
SAD I21	7 x 10 ⁷	0	100	3,000,000	ND	12.5
SAD NM7	2 x 10 ⁷	0	100	600,000	0	ND
SADTMD23	4 x 10 ⁶	0	100	120,000	0	ND

CLAIMS

1. Recombinant rabies virus mutant comprising a mutation in the viral genome, whereby said mutation comprises at least a substitution of the Arg₃₃₃ codon with a codon that differs by three nucleotides from said Arg₃₃₃ codon.
2. A mutant according to claim 1 characterised in that said mutant is a mutant of the SAD strain.
3. A mutant according to claims 1 or 2 characterised in that the Arg₃₃₃ codon is substituted with a GAC triplet or a CAC triplet.
4. A mutant according to claim 3 characterised in that the mutant is recombinant rabies virus mutant strain SAD D29.
5. Recombinant rabies virus mutant according to any of claims 1-4 for use as a therapeutic or prophylactic agent
6. Recombinant rabies virus mutant according to any of claims 1-4 for use in a vaccine.
7. Live attenuated anti-rabies vaccine characterised in that said vaccine comprises a recombinant rabies virus mutant according to claims 1-4 and a pharmaceutical acceptable carrier.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/09101

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N7/04 A61K39/205 A61P31/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 583 998 A (VIRBAC SA) 23 February 1994 (1994-02-23) cited in the application page 2, line 28 - line 57 page 4, line 28 - line 50 claims 1-9 ---	1,2,4-7
A	EP 0 350 398 A (VIRBAC SA) 10 January 1990 (1990-01-10) cited in the application page 3, column 4, line 34 - line 65 ---	1-7
A	EP 0 202 142 A (CENTRE NAT RECH SCIENT) 20 November 1986 (1986-11-20) the whole document --- -/--	1-7

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

23 February 2000

Date of mailing of the international search report

01/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fernandez y Branas, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/09101

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TUFFEREAU C. ET AL: "Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice"</p> <p>VIROLOGY, vol. 172, 1989, pages 206-212, XP002103796 the whole document</p> <p>-----</p>	1-7

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/09101

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0583998 A	23-02-1994	FR 2693655 A	21-01-1994
		AT 175877 T	15-02-1999
		BG 61066 B	31-10-1996
		BG 97964 A	25-04-1994
		BR 9302910 A	16-02-1994
		CA 2100591 A	21-01-1994
		CZ 9301402 A	16-02-1994
		DE 69323130 D	04-03-1999
		DE 69323130 T	17-06-1999
		FI 933210 A	21-01-1994
		HR 931065 A	28-02-1995
		HU 69961 A	28-09-1995
		MX 9304349 A	30-06-1994
		PL 299739 A	24-01-1994
		RO 112582 A	28-11-1997
		SI 9300392 A	30-06-1994
		SK 76193 A	08-06-1994
		US 5853735 A	29-12-1998
EP 0350398 A	10-01-1990	FR 2633832 A	12-01-1990
		AT 90878 T	15-07-1993
		DE 68907280 T	02-12-1993
		DK 170393 B	21-08-1995
		ES 2058570 T	01-11-1994
EP 0202142 A	20-11-1986	FR 2580176 A	17-10-1986
		AT 49885 T	15-02-1990